Matching articles for "Opioid-induced constipation"
Naldemedine (Symproic) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • December 4, 2017; (Issue 1535)
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third...
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third oral
peripherally-acting mu-opioid receptor antagonist
(PAMORA) to be approved for this indication; naloxegol
(Movantik) and methylnaltrexone (Relistor) were
approved earlier.
Naloxegol (Movantik) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • September 28, 2015; (Issue 1478)
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain....
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain. It is the only oral opioid antagonist approved for
this indication in the US.
Lubiprostone (Amitiza) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • June 10, 2013; (Issue 1418)
The FDA has approved use of lubiprostone (Amitiza)
for treatment of opioid-induced constipation in adults
with chronic non-cancer pain. The drug was previously
approved for chronic idiopathic constipation...
The FDA has approved use of lubiprostone (Amitiza)
for treatment of opioid-induced constipation in adults
with chronic non-cancer pain. The drug was previously
approved for chronic idiopathic constipation and irritable
bowel syndrome with constipation.
Methylnaltrexone (Relistor) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • August 11, 2008; (Issue 1292)
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced...
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced illness (such as incurable cancer or end-stage chronic obstructive pulmonary disease) who are receiving palliative care.